Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | NAAA | Q02083 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250059 | 0.78 | CYP19A1 (0.43) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL11991229 | 0.76 | CYP19A1 (0.47) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL13287232 | 0.76 | CYP19A1 (0.41) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL14536173 | 0.75 | CYP19A1 (0.41) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL24134017 | 0.73 | CYP19A1 (0.45) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL13953762 | 0.73 | CYP19A1 (0.45) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL12504243 | 0.73 | CYP19A1 (0.45) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL14536125 | 0.73 | CYP19A1 (0.40) | CYP19A1EPHX1HTTNAAANPC1 | |
| SCHEMBL12292434 | 0.73 | MAPT (0.43) | NPC1RAB9ACYP2C19CYP3A4TSHR | |
| SCHEMBL4677620 | 0.72 | CYP19A1 (0.50) | CYP19A1EPHX1HTTNAAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012074122-A1 | NEGATIVE PATTERN FORMING METHOD AND RESIST PATTERN | FUJIFILM CORPORATION (JP) | 2012-06-07 | — | — | WO | disclosed |
| US-20110229832-A1 | PATTERN FORMING METHOD USING DEVELOPER CONTAINING ORGANIC SOLVENT AND RINSING SOLUTION FOR USE IN THE PATTERN FORMING METHOD | FUJIFILM CORPORATION (JP) | 2011-09-22 | — | — | US | disclosed |
| EP-1974914-A2 | Lithographic printing plate precursor and method of preparing lithographic printing plate | FUJIFILM Corporation (JP) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110229832-A1 | PATTERN FORMING METHOD USING DEVELOPER CONTAINING ORGANIC SOLVENT AND RINSING SOLUTION FOR USE IN THE PATTERN FORMING METHOD | RER1, RARA, RARG | CYP19A1 1890/4885EPHX1 416/4885HTT 4666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.